Computational Solutions for Life Threatening Diseases

Company Details

A2A Pharmaceuticals has designed new drug candidates for Leukemia and other cancers. A2A has also developed New drug alternatives for other life threatening diseases.

A2As technology platform allows for optimization of efficacy with minimization of toxicity much faster and more precisely than competitors.

The track record for development of new drug candidates has been proven with work done for other pharmaceutical companies. Details are available on request.

Company People

Matthew Welsch

Matthew Welsch
Consultant & Co-Founder

Sridhar Vempati

Sridhar Vempati
Board Member & Co-Founder

Edward Painter

Edward Painter
CEO & Co-Founder


Please tell us a little bit about yourself and why you'd like to get connected.

A2A + SOSV will follow up with you via email.

** If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More

You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.